OS Therapies (NYSE:OSTX - Get Free Report) was upgraded by EF Hutton Acquisition Co. I to a "strong-buy" rating in a note issued to investors on Tuesday, Zacks.com reports.
Separately, Brookline Capital Management upgraded OS Therapies to a "strong-buy" rating in a research report on Thursday, August 22nd.
View Our Latest Research Report on OS Therapies
OS Therapies Trading Down 2.9 %
Shares of NYSE OSTX traded down $0.12 during midday trading on Tuesday, hitting $4.00. 23,991 shares of the company's stock were exchanged, compared to its average volume of 358,468. OS Therapies has a twelve month low of $2.51 and a twelve month high of $4.90.
OS Therapies (NYSE:OSTX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that OS Therapies will post -0.47 earnings per share for the current year.
OS Therapies Company Profile
(
Get Free Report)
OS Therapies Incorporated is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. Our mission is to address the significant need for new treatments in cancers of the bone in children and young adults.
Read More
Before you consider OS Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OS Therapies wasn't on the list.
While OS Therapies currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
